Counterfactual Explainability Framework With CycleGAN And Counterfactual-Classifier Alignnment Score for Retinal Disease Classification
Mirrored from arXiv — Machine Learning for archival readability. Support the source by reading on the original site.
Computer Science > Machine Learning
Title:Counterfactual Explainability Framework With CycleGAN And Counterfactual-Classifier Alignnment Score for Retinal Disease Classification
Abstract:Automated detection of vision impairing retina-based ocular conditions from fundus images is important for early screening, timely referral and reducing dependency on specialist-only assessment, for which neural network-based deep learning (DL) models have been widely utilized. However, explainability of the DL frameworks remains a major bottleneck for clinical adoption, particularly when model decisions are not linked to retinal regions that are clinically meaningful. To address this issue, this study presents CounterFundus, a novel CycleGAN-driven counterfactual explainability framework, integrating EfficientNet-B5-based retinal disease detection with visually interpretable disease-to-normal fundus image translation. For each pathological image, the counterfactual yielded by the CycleGAN generator represents an estimated healthy counterpart and the resultant difference map is utilized to localize disease-associated retinal changes. Unlike conventional post-hoc saliency methods, CounterFundus provides counterfactual explanations through visually plausible disease-to-normal retinal translation. Thereafter, to quantify the spatial agreement between counterfactual difference maps and classifier saliency, the Counterfactual-Classifier Alignment Score (CCAS) is introduced, embedding Spearman correlation, binary IoU and pointing accuracy into a single assessment protocol. To this end, EigenCAM-aligned evaluation demonstrates that the generated counterfactual explanations remain spatially consistent with classifier-relevant retinal evidence across all CCAS dimensions. Along with that, ablation studies further confirm that CCAS-filtered counterfactual augmentation improves the downstream classification performance in fundus images, establishing CounterFundus as a clinically-grounded, explainable artificially intelligence (XAI) framework for retinal disease detection.
| Comments: | 8 pages, 9 figures, 9 tables |
| Subjects: | Machine Learning (cs.LG); Computer Vision and Pattern Recognition (cs.CV) |
| Cite as: | arXiv:2607.21068 [cs.LG] |
| (or arXiv:2607.21068v1 [cs.LG] for this version) | |
| https://doi.org/10.48550/arXiv.2607.21068
arXiv-issued DOI via DataCite (pending registration)
|
Submission history
From: Kritanu Chattopadhyay [view email][v1] Thu, 23 Jul 2026 09:00:31 UTC (21,451 KB)
Access Paper:
- View PDF
- HTML (experimental)
- TeX Source
References & Citations
Bibliographic and Citation Tools
Code, Data and Media Associated with this Article
Demos
Recommenders and Search Tools
arXivLabs: experimental projects with community collaborators
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.
Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.
Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
More from arXiv — Machine Learning
-
LoKiFormer: Locality-aware Attention with Decoupled Knowledge Memory for Efficient Large Language Model Pretraining
Aug 14
-
Which Site, and When: A Free-Satellite-Data Test of Himalayan Glacial Lake Bursts, Landslides, and Ice Floods
Aug 14
-
MARCH: Scaling Recurrent Memory with Content-Routed State Anchors
Aug 14
-
Multi-AUV Ad-hoc network-based Target Tracking: A Value Gradient Guidance Multi-Agent Diffusion Reinforcement Learning Approach
Aug 14
Discussion (0)
Sign in to join the discussion. Free account, 30 seconds — email code or GitHub.
Sign in →No comments yet. Sign in and be the first to say something.